Malignant Peripheral Nerve Sheath Tumor
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, the KIS gene was overexpressed in NF1-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs) as compared to dermal neurofibroma which suggests a possible implication of KIS in the genesis of NF1-associated tumors.
|
12782393 |
2003 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
On the other hand, the KIS gene was overexpressed in NF1-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs) as compared to dermal neurofibroma which suggests a possible implication of KIS in the genesis of NF1-associated tumors.
|
12782393 |
2003 |
Vitelliform Macular Dystrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
One locus on 1q23 (UHMK1, rs16863247, P=4.1×10(-7) for femoral neck BMD and P=3.2×10(-6) for total hip BMD) was a novel BMD signal.
|
27424934 |
2016 |
Becker Muscular Dystrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
One locus on 1q23 (UHMK1, rs16863247, P=4.1×10(-7) for femoral neck BMD and P=3.2×10(-6) for total hip BMD) was a novel BMD signal.
|
27424934 |
2016 |
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results demonstrate the effectiveness of an aryloxazole moiety in targeting brain tumors and suggest KIST-G1 as a potent anti-glioblastoma agent.
|
31569420 |
2019 |
Nerve Sheath Tumors
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human.
|
12782393 |
2003 |
Pouchitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
SNP genotyping was performed for 8 SNPs reportedly associated with UCAC and pouchitis, namely: ELF1 (rs7329174), FCGR2A, (rs1801274), interleukin-1β (IL-1B; rs1143627), ITLN1 (rs2274910), MHC (rs7765379), TNFα (rs1799964), TNFSF15 (rs3810936), and UHMK1 (rs768910), using TaqMan genotyping technologies.
|
31671425 |
2019 |
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The fact that UHMK1 regulates these factors suggests that UHMK1 might be involved in RNA processing and perhaps leukemogenesis.
|
29307747 |
2018 |
Schizophrenia
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
The finding of allelic association with markers in the UHMK1 gene might help explain why it has not been possible, despite great effort, to satisfactorily confirm previously reported associations between schizophrenia and the genes RGS4 and NOS1AP/CAPON.
|
18414510 |
2008 |
Schizophrenia
|
0.350 |
Biomarker
|
disease |
LHGDN |
The finding of allelic association with markers in the UHMK1 gene might help explain why it has not been possible, despite great effort, to satisfactorily confirm previously reported associations between schizophrenia and the genes RGS4 and NOS1AP/CAPON.
|
18414510 |
2008 |
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
The finding of allelic association with markers in the UHMK1 gene might help explain why it has not been possible, despite great effort, to satisfactorily confirm previously reported associations between schizophrenia and the genes RGS4 and NOS1AP/CAPON.
|
18414510 |
2008 |
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
These results provide preliminary evidence that the UHMK1 gene increases susceptibility to schizophrenia.
|
16978587 |
2007 |
Schizophrenia
|
0.350 |
Biomarker
|
disease |
LHGDN |
These results provide preliminary evidence that the UHMK1 gene increases susceptibility to schizophrenia.
|
16978587 |
2007 |
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
These results provide preliminary evidence that the UHMK1 gene increases susceptibility to schizophrenia.
|
16978587 |
2007 |
Congenital chromosomal disease
|
0.010 |
Biomarker
|
group |
BEFREE |
We analysed PAX5/BSAP expression by Northern and Western blotting in a panel of haematological tumour cell lines with other chromosome abnormalities in comparison with that of KIS-1.
|
9722295 |
1998 |
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
Childhood Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
MYELODYSPLASTIC SYNDROME
|
0.010 |
Biomarker
|
group |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
Adult Acute Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
Diffuse Large B-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |
Adult Diffuse Large Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |